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Cutaneous T-cell lymphomas (including rare
subtypes). Current concepts. II.
Cutaneous T-cell lymphomas (CTCL)which account for about 80% of skinlymphomas, are a heterogeneous
group of diseases with respect to clinical
presentation, outcome, histologic and im-
munophenotypic features. Both the recent
WHO lymphoma classification1 and the
EORTC cutaneous lymphoma classification2
have paid a special attention to the catego-
ry of cutaneous T/NK lymphomas which has
been divided into several subtypes. A com-
parison between the terminology adopted
by these two schemes reveals a wide con-
sensus on the categorization of almost 90%
of CTCL subtypes. Minor controversies exist
on the classification of the CD30 large cell
T-cell lymphoma with non-anaplastic mor-
phology, the use of the term peripheral T-
cell lymphoma not otherwise specified and,
to a lesser extent, the poorly defined cate-
gory of the so-called CD56+ blastic NK lym-
phoma/leukemia. Future studies on such rare
issues will probably reduce the divergences
further. In this paper we describe the clini-
copathologic features of the most frequent
T/NK-cell lymphoma subtypes.
Mycosis fungoides and
Sézary’s syndrome (WHO 01)
Clinical features and morphology
Mycosis fungoides (MF) is the commonest
type of cutaneous lymphoma3 and mostly
affects adults and the elderly (M/F ratio 2:1;
average age about 50 years); sporadic cases
have also been reported in children and
young adults.4 The classical form of MF is
clinically characterized by progressive phas-
es (patch, plaque and tumor stage or ery-
throderma) and a proctracted natural histo-
ry. The early phase consists of erythematous,
flat patches (measuring from 1 to 5 cm in
diameter). As the patches become increas-
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Background. Cutaneous T-cell lymphomas (CTCL) represent about the 80% of skin lym-
phomas and comprise a heterogeneous group of diseases with respect to clinical presenta-
tion, outcome, histologic and immunophenotypic features. In the recent years, data have been
accumulated indicating that clinical and biological differences exists between primary nodal
and primary extranodal lymphomas. 
Information Sources. On such bases, the cutaneous lymphoma classification by the EORTC
(European Organization for Cancer Research and Treatment) but also the recent general lym-
phoma classification, by the WHO (World Health Organization), have dedicated special atten-
tions to the cutaneous lymphomas including the T and NK-cell subtypes. This paper reviews
the most significative subtypes of T-cell lymphoma that affect the skin primarily or second-
arily. 
State of the Art. Apart from mycosis fungoides with its variants forms and the Sezary’s
syndrome, we have focused on the CD30+ primary cutaneous lymphoproliferative disorders
(PCLD) (25% of all CTCL), a fascinating spectrum of disease, extending from lymphomatoid
papulosis (LyP) trough to CD30+ large cell lymphoma. These disorders have in common large
atypical CD30+ cells and a frequent spontaneous regression of the skin lesions associated with
a relatively favourable outcome (excellent in LyP). The identification of this group of skin dis-
orders is crucial for the patients since most of CD30+ PCLD are indolent diseases that do not
warrant aggressive treatment. Others types of CTCL include the heterogeneous category of
peripheral T-cell lymphoma not otherwise specified (NOS), subcutaneous panniculitis-like T-
cell lymphoma and the still controversial group of the cytotoxic lymphomas. 
Perspectives. Notably, the latter two subtypes have special relevance to the clinicians
because (i) subcutaneous panniculitis-like T-cell lymphoma may be associated with the
hemophagocytic syndrome;  (ii) skin lesions in cytotoxic lymphomas may represent the first
mainifestation of an otherwise systemic disease.
Key words: T-cell lymphomas, subtypes. 
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ingly infiltrated they evolve into palpable reddish-brown
infiltrated plaques with well-marginated borders.
Patients with MF plaques may also have typical patch
lesions contiguous with the plaques or at other body
sites. Patch and plaque lesions usually have an asym-
metrical distribution, mostly involving the buttocks,
lower trunk, groin, axillae, and breasts. In the late stage
of MF the patients show a combination of patches,
plaques and nodular/tumor lesions (the latter may
progress from pre-existing plaques or arise de novo) or
diffuse erythroderma often sparing flexural areas.
Although the proctracted natural history is one of the
peculiar clinical features of MF, the rapidity of progres-
sion through the various clinical stages is unpredictable.
MF patients may have regional nodal enlargement and
a grading system for nodal involvement ranging from I
(no involvement) to III (diffuse nodal infiltration by the
lymphoma cells) has been proposed. However, in
advanced clinical stages of MF the lymphoma popula-
tion may spread to various organs other than skin and
lymph nodes.
Histologically, the MF cellular infiltrate is composed
of atypical T lymphocytes with hyperconvoluted (cere-
briform) or pleomorphic nuclei, which exhibit a vari-
able degree of epidermotropism. Usually, the cytologi-
cal features and distribution patterns of the MF cellu-
lar infiltrate correlate closely with the clinical stage of
the disease. In the patch lesions the lymphoma popu-
lation consists of small T lymphocytes with few atypi-
cal cells; the infiltrate involves the upper dermis with a
patchy-perivascular, lichenoid or band-like pattern; epi-
dermotropism with single cell exocytosis may occur, but
the intraepidermal clusters of atypical cells (Pautrier’s
microabscess) are rare at this phase. The epidermis may
be acanthotic, hyperkeratotic or psoriasiform (in case of
erythroderma); fibrosis of the papillary dermis and ves-
sel hyperplasia in the superficial dermis may be present.
Much has been written on cytologic features set forth
as characteristic of early patch MF, but evidence has
accumulated showing that whereas some of these cri-
teria may be helpful others are not.5 Widely accepted
morphologic criteria favoring a diagnosis of MF include:
presence of haloed convoluted lymphocytes of approx-
imately the same width as the basal keratinocytes,
Pautrier’s microabscesses, disproportionate exocytosis,
and lymphocytes aligned within the basal layer. In the
plaque phase the lymphoma infiltrate is dense and
shows a dermal band-like growth pattern; intraepider-
mal Pautrier’s microabscesses may be found in at most
25% of cases. The lymphoma cells are small to medium-
sized, pleomorphic and admixed with eosinophils and
plasma cells. In the tumor phase, the lymphoma infil-
trates the whole dermis and often subcutis with a nodu-
lar and/or diffuse growth pattern. The lymphoma pop-
ulation consists of medium-sized atypical pleomorphic
cells; in this phase epidermotropism can be lost. In
about 50% of the cases scattered large atypical pleo-
morphic to anaplastic cells can be found; if the num-
ber of the large cells exceeds 25% of the whole infil-
trate, transformation/progression into a secondary large
cell lymphoma can be hypothesized.
Immunohistochemistry, molecular biology
and cytogenetics
In cases of classical MF the lymphoma cells have a T-
helper/memory antigenic profile (CD2+; CD3+; βF1+;
CD4+; CD8–; CD5+; CD45RO+), with frequent loss of the
CD7 antigen; rare cases with a T-suppressor CD8+/CD4−
phenotype have been reported. Sporadically, reactivity
for the CD15 has been observed in advanced tumor
stages of MF.6 The lymphoma cells may also show reac-
tivity for CD30 in the plaque and tumor stages; howev-
er, CD30 expression in a previously negative MF case is
often associated with progression into large cell lym-
phoma and a poor outcome. T-cell receptor (TCR) gene
rearrangement is frequent in most cases of MF in the
plaque and/or tumor stages, but is often absent in ear-
ly MF. Complex karyotypes have been documented in
many MF patients especially in advanced disease phas-
es, but no specific genetic abnormalities have been
associated with MF.
Differential diagnoses
The diagnosis of MF relies on the combination of clin-
ical presentation and features in addition to  histo-
pathologic findings (epidermotropic lymphoma charac-
terized by a dermal infiltrate of T-lymphocytes with
cerebriform nuclei and Pautrier’s microabscesses). How-
ever, because of the heterogeneity of its clinical and
histologic patterns, the early MF may be hardly or not
distinguishable (both clinically and histologically) from
a number of conditions (e.g. actinic reticuloid, pseudo-
T-cell lymphomas, lymphomatoid papulosis type B)
which may either precede, occur concurrently or simu-
late MF. The difficulty in diagnosing MF is mainly due
to its natural history that tends to evolve slowly, and
patients often carry a long-standing diagnosis of
eczematoid, lichenoid or psoriasiform superficial der-
matitis before a definitive diagnosis can be reached.
The major diagnostic difficulties regard large plaque
parapsoriasis in which the patients have slightly scaly,
erythematous, atrophic patches with or without poik-
ilodermatous changes that cannot be distinguished
from MF patches.7 Inconclusive biopsy results may be
explained by the predominance of reactive T-lympho-
cytes and lack of specific histologic criteria for a diag-
nosis of early MF. The modern ancillary techniques (i.e.
immunohistochemistry and molecular biology) have
failed to fill this diagnostic void. Modifications of the
antigenic profile of the T-cell infiltrate (i.e. loss of CD7)
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have also been found in inflammatory dermatoses;8 thus
the presence of an aberrant T-cell phenotype, except for
CD7 loss, is often considered as a valuable diagnostic
adjunct. Similarly the rate of false-negative results and
the increasingly frequent identification of clones in
lichen planus, pityriasis lichenoides, spongiotic der-
matitis, etc.,9 suggests that a demonstration of a clon-
al proliferation of T-cells does not establish a diagnosis
of MF or even, necessarily, of a lymphoma. In conclu-
sion, the diagnosis of MF presently still relies on care-
ful combination of clinical, morphofunctional and
molecular information and, often, prolonged follow-up
with repeated biopsies. 
Juvenile mycosis fungoides
MF may sometimes affect children, adolescents and
young adults (less than 35 years) and the onset of MF
during the first two decades is probably more common
than is generally recognized. Thus MF should be includ-
ed in the differential diagnosis of chronic dermatoses
(atopic dermatitis, pityriasis lichenoides) which can
affect children and adolescents. Usually these young
patients have limited round or oval erythematosqua-
mous patches and plaques (T1-disease); less frequent-
ly papulonodular, follicular, annular or hypopigmented
lesions may be observed; erythroderma is rare. Normal-
ly the histologic and immunophenotypic features of cel-
lular infiltrate in juvenile MF are similar to those of the
adult forms. However special cases have been reported10
in which the histologic examination of the patch/plaque
lesions reveals a prominent epidermotropism of the
lymphoma cells which show a peculiar CD8+ cytotoxic
phenotype. The exact relationship of these unusual cas-
es with respectively the spectrum of cytotoxic CTCL and
some special variants of LyP with a natural killer phe-
notype is to date unexplored. The disease-specific sur-
vival of younger and older patients is similar.
MF variants
Numerous clinical and/or histopathological variants
of MF have been described in the past but a wide con-
sensus has now been achieved to restrict the term MF
to the classical form of the disease. Presently, only three
major MF variants are recognized in both the WHO and
EORTC classifications. These are (i) MF with follicular
mucinosis; (ii) pagetoid reticulosis and (iii) granuloma-
tous slack-skin disease (this latter included among the
provisional entities by the EORTC classification).
(i) MF associated with follicular mucinosis11 is clini-
cally characterized by the presence of follicular erythe-
matous papules and plaques often involving the head
(scalp) and neck areas (Figure 1A). In other skin regions
the same patients may show plaques and/or nodules of
otherwise classical MF. Patients with MF associated with
follicular mucinosis may develop follicular cysts (which
harbor MF infiltrate in hair walls) and may mimic MF
nodular/tumor lesions. Histologically the lymphoma
population consists of a follicular rather than epider-
motropic infiltrate of small to medium-sized pleomor-
phic CD4+ T-lymphocytes associated with a variable
degree of mucin deposition within and around the hair
follicles (Figure 1B). TCR clonal rearrangement can be
demonstrated in most cases. (ii) Pagetoid reticulosis12 is
histologically characterized by a strictly epidermal atyp-
ical lymphoid infiltrate. Clinically a distinction has been
made between patients with localized (Woringer-Kolopp
disease) or multiple (Ketron-Goodman disease) skin
lesions. The prognostic outcome seems to be excellent
in the localized form of the disease, whereas the cases
with multiple lesions pursue an indolent course like the
classical MF. The patients have large, erythematous,
scaly or hyperkeratotic verrucous patches and plaques
(Figure 2A). Lesions usually grow slowly and are local-
ized mostly on the lower part of the limbs. The lym-
phoma cells show an exquisite epidermotropism and, in
Figure 1. A. Mycosis
fungoides (MF) asso-
ciated follicular muci-
nosis: the patient
presents erythema-
tous papules and pla-
ques involving the
head. B. Histological-
ly the MF lesion con-
sists of a follicular
rather than epider-
motropic infiltrate of
small to medium-
sized lymphocytes
(HE, ×200).
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most cases, they have a peripheral CD8+/CD4− or
CD4+/CD8−T-cell phenotype, with frequent expression of
the Ki-1/CD30 antigen, at least in a proportion of the
lymphoma cells (Figure 2B). TCR clonal rearrangement
can be demonstrated in most cases. Various authors
presently consider that the term pagetoid reticulosis
must be restricted to the localized form of the disease
only, whereas the disseminated forms of the disease
might represent cases of γ-δ or CD8+ aggressive-cyto-
toxic epidermotropic T-cell lymphomas. (iii) granulo-
matous slack skin disease13 is clinically characterized by
the presence of slowly developing folds of atrophic skin
often involving the neck, axillae and buttocks (Figure
3A). Histologically the lymphoma population diffusely
involves the whole dermis and subcutis and consists of
a polymorphous appearing infiltrate of small to medi-
um-sized-pleomorphic CD4+ T-lymphocytes admixed
with CD68+ macrophages, a variable number of giant
cells (exibiting elastophagocytosis) and scattered gran-
ulomas (Figure 3B). TCR clonal rearrangement can be
demonstrated in most cases. Patients with this unusu-
al variant of MF frequently have other associated lym-
phomas (mostly Hodgkin’s lymphoma).
Sezary’s syndrome
Sezary’s syndrome (SS) is a rare disease14,15 that occurs
exclusively in adults and elderly patients who develop
erythroderma, generalized lymphoadenopathy and a
leukemic blood picture with a count of at least 1000
atypical convoluted Sézary’s T-cells per mm3. In addition
an abnormal CD4/CD8 ratio (at least >10) and the same
TCR clonal rearrangement in the skin and peripheral
blood must be demonstrated. Cutaneous SS lesions are
similar, but usually more intense than those in erythro-
dermic MF; patients may show alopecia, pruritus and
often palmoplantar hyperkeratosis. Histologically, in the
skin, the lymphoma infiltrate mimics that of MF, con-
sisting of small to medium sized pleomorphic T lym-
phocytes, but the epidermotropism may be lost. The
demonstration of an increased number of CD4+ T-lym-
phocytes, with an increased percentage of CD4+/CD7− or
CD4+/CD26− lymphocytes and an elevated concentra-
Figure 2. A. MF, pagetoid reticulosis: the patient presents localized (Woringer-Kolopp disease) erythematous, scaly,
infiltrated plaques. B. The lymphoma cells show an exquisite epidermotropism (×400).
Figure 3. A. MF, granulomatous slack skin variant: the patient has folds of atrophic skin involving the groin. B. The
MF lymphoma infiltrate consists of small to medium-sized lymphocytes admixed with histiocytes and scattered giant
cells (HE, ×200).
                     
tion of lactate dehydrogenase (LDH) are useful diag-
nostic parameters. The bone marrow is often infiltrat-
ed (sparse and interstitial pattern). SS is an aggressive
disease with a poor outcome (the 5-year overall survival
is between 10-20%). Progression or transformation into
a large cell lymphoma may occur as a terminal event.
However cases with an intermediate or indolent pro-
gression may be observed, showing leukemic blood
involvement, with mild cutaneous erythroderma and
absence of lymphadenopathy.
Outcome and therapy
MF is generally characterized by an extremely slow
and long natural history. Patients with limited disease
usually have an excellent prognosis with a survival sim-
ilar to that of the background population; in such cas-
es, the disease remains confined to the skin for many
years. The risk of extracutaneous spread (initially to
regional lymph nodes but later also to the spleen, lungs
and liver) may occur as the stage or extent of disease
increases. In the more advanced stages, the prognosis
is poor with possible transformation into a high grade
T-cell lymphoma. Infections (e.g. Staphylococcus
aureus) still represent one of the major fatal complica-
tions in advanced stage MF. Treatment of early stage of
MF16 includes local or systemic steroids, topical nitrogen
mustards (NH2, BCNU), local or systemic psoralens in
association with UV-A irradiation (PUVA, Bath-PUVA),
interferon-α2a/b, retinoids, or a combination of the last
three modalities. Extracorporeal photophoresis can be
used in erythrodermic phase. Local radiotherapy, metho-
trexate (10-20 mg/weekly) and cyclophosphamide (50-
100 mg/day) can also induce partial or complete clini-
cal remissions in stage II-IV of the disease. Experimen-
tal trials with vaccines (dendritic cells immunized by
using tumor-specific sequences or stimulated by lysate
of tumor cells) have also been done. Total body irradi-
ation has now been abandoned or is restricted to MF in
later stages, in which systemic mono or poly-
chemotherapy, autologous or allogeneic bone marrow
transplantation can also be used. However, in advanced
MF cases the response is unsatisfactory in most cases,
in spite of aggressive therapy. Stem cell transplanta-
tion has recently been attempted in CTCL, including cas-
es of advanced stages MF, with encouraging results.17
Primary cutaneous CD30+
lymphoproliferative disorders
(lymphomatoid papulosis, primary
cutaneous anaplastic large cell
lymphoma and borderline lesions)
Definition, epidemiology and clinical features
A spectrum of CD30+ primary cutaneous lymphopro-
liferative disorders (PCLD) with a relatively favorable
prognosis has been described.18 This spectrum includes
lymphomatoid papulosis (LyP), (anaplastic/pleomorphic)
large cell CD30+ lymphoma (LCL) and borderline lesions,
the latter showing clinicopathologic features in
between LyP and LCL. Cases previously clinically diag-
nosed as regressing atypical histiocytosis (RAH) are now
considered to be LCL with prominent regressive fea-
tures. Apart from MF, the CD30+ PCLD account for 25%
of all primary CTCL. The features common to all these
PCLD are large atypical CD30+ cells sometimes resem-
bling Hodgkin and Sternberg-Reed (HSR) cells and, clin-
ically, a frequent partial or complete spontaneous
regression of the skin lesions. 
Lymphomatoid papulosis
Clinical features and morphology
LyP is a self-healing rhythmic, paradoxical often gen-
eralized eruption histologically mimicking a malignant
lymphoma, but clinically benign.19 LyP presents as recur-
rent crops of reddish papulo-nodular lesions which
regress spontaneously (within few weeks) leaving only
a small scar or area of altered pigmentation. It usually
affects adults but less frequently also elderly patients
and children. The trunk and extremities, other than the
palms and soles, are the most frequently affected areas
(Figure 4A). Some patients may have several skin erup-
tions within a short period of time, others may have
only a few over several years. Classical LyP lesions
progress through four clinical stages referring to the
natural history and age of the lesions: stage I, early
lesions (erythematous dermal papule); stage II, devel-
oping lesions (clinical features in between stage I and
stage III); stage III, fully developed lesions (hemorrhag-
ic/ulcero-necrotic or crusted papular or nodular lesion);
stage IV, resolving lesions (occasionally leaving a vari-
oliform scar or a small area of altered pigmentation).
Histologically, the classic LyP lesions show a wedge-
shaped pattern of dermal involvement with superficial
and deep perivascular lymphoid infiltrates (Figure 4B).
LyP cellular infiltrates consist of CD30+ atypical cells,
which may be scattered or in small clusters (2-5 atyp-
ical cells), admixed with a reactive cellular background
(neutrophils, eosinophils and histiocytes) (Figure 4C-D).
The above described composition of LyP cellular infil-
trate corresponds to the LyP type A described by
Willemze et al.,20 who also defined two additional sub-
types of LyP (type B and type C). LyP type B consists of
a band-like infiltrate of small atypical lymphocytes with
cerebriform nuclei and a few inflammatory cells (includ-
ing eosinophils), but lacking the large atypical CD30+
cells. LyP type C has been described as a nodular infil-
trate of cohesive sheets of large atypical CD30+ cells
admixed with a variable number of inflammatory cells.
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M. Paulli et al.
                        
haematologica 2004; 89(11):November 2004
Cutaneous T-cell lymphomas
1377
However it is relevant to note that (i) LyP type B is often
histologically indistinguishable from early MF and the
absence of CD30+ cells enhances the diagnostic diffi-
culties (ii) LyP type C is histologically indistinguishable
from CD3+ LCL and/or borderline lesions. However, both
LyP type B and C seem to differ both histologically and,
in part, clinically from the LyP features originally
described by Macaulay. Thus, the diagnosis of any LyP
other than the classical type A requires caution and
should be made only after other differential diagnostic
possibilities have been evaluated and excluded.
Immunohistochemistry, molecular biology
and cytogenetics
In the classical (type A) LyP the atypical CD30+ cells
have a CD4+ T-helper phenotype (CD3+,CD4+,CD8−);21
aberrant phenotypes with loss of one or other of the T-
cell antigens may occur. Atypical LyP cells are also pos-
itive for various cytotoxic granule-associated proteins
(TIA-1, perforin and granzyme B).22 Rare cases of LyP
with a natural killer phenotype (CD30+;CD56+;CD3–;
CD4–;CD8−) have been reported23 and CD15 may be
expressed in cases of LyP associated with MF or classi-
Figure 4. A. Lymphomatoid papulosis (LyP): the patient presents reddish papulo-nodular lesions involv-
ing the trunk and extremities. B. Histologically, the classical LyP shows a typical wedge-shaped dermal
cellular infiltrate. (HE, ×20) consisting of (C) large atypical cells admixed with a reactive cellular back-
ground (neutrophils, eosinophils and histiocytes) (HE, ×200). D. The large atypical LyP cells strongly
express the CD30/Ki-1 antigen (membrane and paranuclear dot-like reactivity). (APAAP, ×200).
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cal Hodgkin’s lymphoma. Clonal rearrangement of TCR
genes can be demonstrated in about 40% of cases and,
indeed, a  higher percentage of clonal rearrangement
has recently been reported24 in a study using TCR-γ
analyses on DNA extracted from CD30+ laser-microdis-
sected cells instead of on DNA obtained from the whole
cellular infiltrate. It is currently widely accepted that
neither t(2;5), nor ALK protein expression is found in
CD30+ PCLD.25 Searches for Ebstein Barr virus (EBV) RNA
or EBV gene products are similarly negative. 
Differential diagnoses
LyP must be differentiated from other CD30+ PCLD,
rare cases of primary or secondary cutaneous Hodgkin’s
lymphoma and also from reactive CD30+ skin lymphoid
infiltrates including follicular lymphoid hyperplasia with
a high content of activated CD30+ blast cells,26 cuta-
neous infection by parapoxvirus (i.e. milker’s nodule)27
and drug reactions.28
CD30+ large cell lymphoma
Clinical features and morphology
LCL usually presents as a single or multiple medium-
sized to large reddish nodules or tumors (Figure 5A) that
may initially show temporary regression, but often per-
sist; loco-regional lymph node involvement occurs in
about 10% of cases, but visceral spread is rare.29 Cases
previously clinically diagnosed as regressing atypical
histiocytosis (RAH) characterized by a single nodular
lesion (Figure 6A), often superficially ulcerated or crust-
ed, are now considered to be CD30+ ALCL with promi-
nent regressing features.30 CD30+ cutaneous LCL usual-
ly affects adults and elderly patients and less frequent-
ly children and adolescents. Morphologically the LCL
lesions show a grossly nodular and/or diffuse pattern of
dermal involvement with frequent extension to the sub-
cutis (Figure 5B). In some cases the overlying epidermis
may show a variable degree of pseudo-epitheliomatous
hyperplasia, which may be pronounced in the cases pre-
Figure 5. A. CD30+ primary cutaneous anaplastic large cell lymphoma: the patient presents a large reddish tumor lesion.
B: histologically, the lymphoma population is composed of a predominant population of large, anaplastic cells (HE, ×200)
which (C) uniformly and strongly express the CD30/Ki-1 antigen (APAAP, ×400).
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viously classified as RAH. The lymphoma population
consists of large anaplastic cells grouped in large, con-
fluent cohesive sheets; transepidermal elimination
mostly occurs in the RAH forms, which are also char-
acterized by an intense reactive/inflammatory cellular
background. In the WHO lymphoma classification,1 the
category of cutaneous CD30+ LCL only includes cases
displaying the classic anaplastic cytology; in contrast
the EORTC scheme2 identifies three different subtypes of
CD30+ LCL: anaplastic, immunoblastic and pleomorphic.
However, this cytomorphologic differentiation has lim-
ited/no clinical relevance because the outcome of CD30+
cutaneous lymphomas is favorable, irrespectively of the
anaplastic versus non-anaplastic (immunoblastic, pleo-
morphic) cytology.29 Furthermore, at least in some cas-
es, the fixation and embedding procedures might be
responsible for technical artefacts resulting in cyto-
morphological features of the lymphoma cells.
Immunohistochemistry, molecular biology
and cytogenetics
A conditio sine qua non for a diagnosis of CD30+ LCL
is the detection of the CD30 (Figure 5C) in almost 75%
of the lymphoma cells;29 if only scattered positive cells
are found the lymphoma must be classified into anoth-
er subtype. Other antigens expressed include CD25,
HLA-DR, CD71 and EMA, although this last was report-
ed as negative in some previous studies. Most CD30+ LCL
have a peripheral T-helper phenotype (CD3+;CD4+;
CD8–)21 with variable loss of some T-cell markers (i.e.
CD2; CD5; CD7) and expression of cytotoxic granule-
associated proteins (i.e. TIA-1; perforin and granzyme B).
Less than 10% of cases have a CD8+ phenotype and
sporadic cases show a null (non-B, non-T) phenotype.
CD56 expression is rare and, in contrast with previous-
ly published data, its biological and prognostic rele-
vance is unknown. Cutaneous CD30+ LCL are uniformly
negative for CD15. Clonal rearrangement of the TCR
genes can be demonstrated in most primary CD30+
cutaneous LCL, including the majority of cases with a
null (non-B, non-T) phenotype. t(2;5) is not associated
with CD30+ PCLD,25 which also lack the ALK protein.
Recently, an allelic deletion at 9p21-22 was reported31
in a small number of cases of cutaneous CD30+ LCL, but
confirmation on large series of cases is awaited.
Differential diagnoses
CD30+ LCL must be differentiated respectively from
other CD30+ PCLD and large cell pleomorphic/anaplas-
tic, but CD30 negative, primary cutaneous T-cell lym-
phomas. It is also clinically relevant to distinguish
between primary cutaneous CD30+ LCL and second-
ary/transformed CD30+ LCL that have progressed from
other primary cutaneous lymphomas (mostly MF), the
latter being characterized by an aggressive clinical
course and poor outcome. The absence of ALK protein
in the CD30+ PCLD, including LCL, may be useful, par-
ticularly in children and young adults, for distinguish-
ing these lesions from a secondary skin dissemination
of systemic (nodal) CD30+ ALCL which are often ALK
positive. However, caution is required when interpret-
ing  such a finding because cases do exist of systemic
(nodal) but ALK negative CD30+ ALCL, mostly affecting
middle-aged and elderly patients. Loco-regional lymph
node involvement may occur in primary cutaneous
CD30+ LCL, but clinical evidence seems to indicate that
it does not affect prognosis, which remains favorable in
most cases. A partial or less frequently complete spon-
taneous regression of  the lymphoma has been report-
ed (in up to 25% of cases in certain series). Risk factors
predictive for extracutaneous lymphoma spread (10% of
cases) are presently unknown.
Figure 6. A. CD30+ primary
cutaneous lymphoprolifera-
tive disorders: the patient
has several lesions, the
largest (arrow) exhibiting a
clinical appearance consis-
tent with a borderline lesion,
while the other residual
lesions are consistent with
classical LyP. B. Histologi-
cally, the cellular infiltrate of
the borderline lesion shows
a nodular pattern of dermal
involvement, initially extend-
ing to the subcutis. (HE,
x25). C. The cellular infil-
trate consists of clusters of
large atypical cells admixed
with a reactive (LyP-like)
inflammatory background
(HE, ×400).
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Borderline lesions
Within the spectrum of primary cutaneous lympho-
proliferative disorders, the term borderline lesions refers
to a group of cases with divergent clinical features and
histological appearance, preventing them from being
readily distinguished from LyP or CD30+ ALCL.1,32 Instead
of the term borderline lesions the EORTC classification2
has introduced the term LyP type C, to identify cases with
similar clinical and morphological features. We prefer
the term borderline lesions because it fits the ambiguous
features of such rare cases well. Borderline lesions usu-
ally present with solitary, nodular lesions rather than
papular ones, but cases with LyP-like papular appear-
ance have been described (Figure 6A). The lesions may
ulcerate and undergo partial or complete spontaneous
regression. Histologically, they exhibit features in
between LyP and ALCL with a nodular pattern of dermal
involvement, sometimes extending to the subcutis (Fig-
ure 6B). The cellular infiltrate consists of atypical CD30+
anaplastic cells grouped in clusters but often admixed
with a mild to prominent reactive LyP-like cellular back-
ground (Figure 6C). In some areas, mostly in the deepest
part of the lesions, the CD30+ cells may form large con-
fluent sheets. Apoptotic features can be numerous. Asso-
ciated dermal and/or epidermal modifications include
spongiosis, parakeratosis, epidermal pseudoepithelioma-
tous hyperplasia and, often, ulceration. Borderline lesions
are rare and limited data are available on their biologi-
cal features, but it seems that their antigenic and molec-
ular features largely overlap with those just described
for the LyP and CD30+ LCL cellular infiltrate.1 Borderline
lesions must be differentiated from other CD30+ PCLD,
but no reliable clincopathologic criteria exist which allow
a clear-cut distinction between borderline lesions and
LyP or CD30+ LCL. 
CD30+ PCLD: outcome and therapy 
CD30+ PCLD have a very favorable clinical oucome in
most cases. In spite of its postulated association with
malignant lymphoma (up to 20% in certain series and
mostly MF and Hodgkin’s lymphoma),33 LyP has an
excellent prognosis preventing the patients from receiv-
ing unnecessary aggressive treatment.32,34 Possible ther-
apies should therefore be directed mainly at controlling
symptoms or slowing down the rate of relapses. Sys-
temic steroids and PUVA have been used with partial
success; some favorable results have also been achieved
with low-dose methotrexate over a long period of time.
Limited information is available on the prognostic out-
come of the borderline lesions; although it has been
suggested that patients with borderline lesions have a
higher risk of developing a CD30+ LCL than do LyP
patients, most of these cases have a favorable outcome
similar to LyP.30,32 The prognosis of primary cutaneous
CD30+ LCL is good, but less favorable than that of LyP
and borderline lesions because some of the patients
with multifocal skin disease may develop extracuta-
neous disease.32,34 However, the involvement of a single
loco-regional lymph node does not seem to affect prog-
nosis adversely. In cases with disease confined to the
skin, local therapy (i.e surgical excision and radiother-
apy) is recommended; chemotherapy is reserved to cas-
es with multifocal or generalized skin disease at high
risk of visceral spread.
Cutaneous lymphomas expressing a T-cytotoxic
or natural killer cell phenotype
As confirmed by a recent study of the EORTC Cuta-
neous Lymphoma Task Force, “…cutaneous lymphomas
expressing a cytotoxic or natural killer (NK) cell phenotype
represent a group of lymphoproliferative disorders for
Figure 7. A. Subcutaneous
panniculitis-like T-cell lym-
phoma: the patient pres-
ents multiple lipoma-like
subcutaneous nodules
involving the trunk and
extremities. B. The lym-
phoma infiltrates the sub-
cutaneous adipose tissue
and consists of small to
medium-sized pleomorphic
lymphocytes (HE, ×200). C.
Lymphoma cells intensely
express cytotoxic mole-
cules (perforin) (SABC,
×400). 
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which there is currently much confusion and little con-
sensus regarding the best nomenclature and classifica-
tion…”.35 In particular, it is debated whether at least some
of these malignancies can indeed be retained as primary
cutaneous lymphomas or whether they actually repre-
sent the first manifestation of a systemic lympho-
ma/leukemia which involves the skin secondarily. The
major subtypes of T/NK lymphomas listed in the WHO
lymphoma classification1 include the subcutaneous pan-
niculitis-like T-cell lymphoma, the extranodal NK/T-cell
lymphoma, nasal type, and the blastic NK-cell lymphoma.
Subcutaneous panniculitis-like T-cell lymphoma 
Clinical features and morphology: Subcutaneous pan-
niculitis-like T-cell lymphoma (SPLTCL) is a rare, aggres-
sive lymphoma subtype which preferentially infiltrates
the subcutaneous tissue,36 expressing a cytotoxic CD8+
or CD56+ phenotype.37,38 SPLTCL affects both sexes and
people of a broad age range, including children and
young adults. Lymphoma lesions consist of multiple sub-
cutaneous nodules and/or erythematous, infiltrated
plaques (CD8+ cases) or ulcerated skin tumors (CD56+),
mostly located on the trunk, extremities, and face (Fig-
ure 7A). Clinical symptoms include malaise, fatigue,
myalgia and weight loss; manifestations of systemic
involvement are fever, hepatosplenomegaly, mucosal
ulcers and sometimes serosal effusions. Some patients
may develop hemophagocytic syndrome, a complication
often precipitating the clinical course.39 Such cases may
have been diagnosed in the past as malignant cytophag-
ic histiocytic panniculitis (CHP).36 Morphologically, the
lymphoma infiltrate involves the lobules of the subcu-
taneous tissue, resulting in a typical lobular-panniculi-
tis-like pattern (CD8+ cases)(Figure 7B), although in some
cases (usually CD56+) dermal and epidermal involvement
may be seen.37-38 The lymphoma cells are small to medi-
um in size with moderate pale cytoplasm; the nuclei are
round to irregular to indented/pleomorphic and often
hyperchromatic. The lymphoma cells tend to surround
individual fat cells giving these latter a typical rimmed
appearance. A variable number of reactive non-neo-
plastic histiocytes can be found, scattered and close to
the areas of necrosis. Apoptotic bodies (karyorrhectic
nuclear fragments) are a frequent finding but an angio-
centric and/or angiodestructive pattern are not among
the typical histological features of SPLTC.
Figure 8. A. Blastic NK lymphoma/leukemia: the patient presents diffuse reddish to bluish infiltrated plaques. B. Histo-
logically, the skin lesion consists of a densely packed dermal and subcutaneous infiltrate composed of medium to large
cells, sometimes resembling myeloid blasts (HE,×200) which express (C) the CD56/ NCAM antigen (SABC, ×200).
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Immunohistochemistry, molecular biology and
cytogenetics
The lymphoma cells express the CD2+; CD3+; CD45RO+
T-cell phenotype; but may express CD8+; CD4–;
CD45RO+, CD56–, BF1–/+ or the CD56+; CD4–, CD8–/+,
BF1–/+, TCR-δ-1–/+ T-cell associated molecules,40-41 with
expression of cytotoxic molecules (i.e. TIA-1, granzyme
B and perforin) (Figure 7C). Most cases derive from α/β
T-cells but about 10% to 25% of CD56+ PLTCL have a
γ/δ origin.37-38,41 In some cases a minority of the neoplas-
tic cells may express the CD30 antigen. Clonal re-
arrangement of the TCR can be found in most cases;41
search for EBV is negative in most cases.40,41 To date, no
specific genetic features have been associated with this
lymphoma. However, in a child affected by SPLTCL, we
have recently documented defective expression of the
perforin gene (unpublished data), an abnormality that
is known to be associated with familial hemophago-
cytic syndrome.42
Differential diagnoses
The subcutis is a primary site of numerous patholog-
ic changes, most of which are inflammatory. Differen-
tiation from non-neoplastic mainly lobular panniculitis
(erythema induratum-nodular vasculitis, lupus panni-
culitis and connective tissue-related panniculitis, etc.)
and from other subtypes of CTCL mainly relies on the
peculiar clinical features (subcutaneous lesions coupled
with systemic symptoms) of SPLTCL rather than on mor-
phologic and immunophenotypic features which are
less distinctive. However, the presence of a discrete
infiltrate formed by pleomorphic hyperchromatic lym-
phoid cells forming a rim around the individual fat cells
may be indicative of a lymphoma involving the subcu-
taneous tissues, whereas the presence of reactive B-
follicles is indicative of an autoimmune disorder (lupus
panniculitis). A definitive diagnosis of SPLTCL may
require multiple sequential biopsies of the lesions and
confirmation by molecular analyses.
Outcome and therapy
The clinical behavior and outcome of PLTCL is variable
but the median survival is usually less than 3 years. In
most cases this lymphoma has an aggressive clinical
course; nodal and/or visceral spread may occur but in
the end-stage of the disease. Hemophagocytic syn-
drome and sepsis are frequent and often fatal compli-
cations. However, two different studies have recently
reported that patients with SPTCL with a α/β phenotype
have a more favorable prognosis than those with a γ/δ
phenotype.37-38,43 Future studies might clarify whether
these two molecular subtypes should be clinically sep-
arated. To date the choice treatment for  SPTCL consists
of aggressive systemic chemotherapy which, in sporadic
cases, has been followed by autologous bone marrow
transplantation.44
Extranodal NK/T-cell lymphoma,
nasal type
Clinical features and morphology
NK/T-cell lymphoma nasal and nasal type45,46 are rel-
atively frequent in Asia, Mexico, Central and South
America but they only sporadically occur in European
countries. This lymphoma has a predilection for extra-
nodal sites, in particular the nasal cavity and nasophar-
ynx45 but the skin, soft tissues and intestine can also be
involved;47 nodal spread is uncommon. Similar lesions
located on the nose have previously been called lethal
midline granuloma. The patients usually have advanced
stage disease at presentation with multiple extranodal
sites of disease and often peripheral blood involvement;
hemophagocytic syndrome is a possible complication.
Clinically, the skin lesions consist of nodules, frequent-
ly ulcerated, but plaques, purpuric and/or bullous
lesions, erythematous macular-papular rashes and sub-
cutaneous panniculitis-like lesions have also been
observed. The most frequent sites of skin involvement
include the face, trunk and the extremities; nasal dis-
ease may follow presentation in the skin. The histolog-
ical features of this lymphoma are similar irrespective-
ly of the primary disease site (nasal vs extranasal).48 The
Table 1. T-cell and NK- lymphomas (according to the WHO
97 lymphoma classification) with frequent or constant
skin involvement.
Primary cutaneous T-cell lymphomas
Mycosis fungoides
Sèzary’s syndrome
Primary cutaneous CD30+ lymphoproliferative disorders
Subcutaneous panniculitis-like T-cell lymphoma
Other T-or NK-cell Lymphomas with primary or secondary
skin involvement.
Extranodal NK/T-cell lymphoma, nasal type
Blastic NK-cell lymphoma/leukemia
Precursor T-lymphoblastic lymphoma/leukemia
Table 2. Primary cutaneous T-cell lymphomas, other than
MF, listed in the EORTC classification.
Indolent
Large cell CD30+ CTCL
Lymphomatoid papulosis
Aggressive
Large cell CD30 negative CTCL
CTCL, pleomorphic small/medium-sized*
Subcutaneous panniculitis-like T-cell lymphoma*
*: provisional entities.
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lymphoma infiltrates the dermis and subcutis showing
a diffuse growth pattern. Angiogentric and angiode-
structive features are frequent and associated with fib-
rinoid changes, coagulative necrosis and the presence
of numerous apoptotic bodies. The lymphoma cells have
a broad spectrum of cytological appearances from small
to medium-sized to large-anaplastic; however, in most
cases, the predominant lymphoma population consists
of medium to large cells. Nuclei may be irregular, elon-
gated or vescicular; cytoplasm is usually pale to clear
and moderate in amount. The lymphoma population
may be accompanied by a heavy inflammatory back-
ground of histiocytes, plasma-cells and granulocytes
(mostly eosinophils).
Immunohistochemistry, molecular biology
and cytogenetics
The lymphoma cells have a CD2+, CD56+, CD3c+, CD43+,
CD45RO+ phenotype and lack surface CD3;45,46,49other T-
and NK cell markers (i.e. CD4, CD5, CD8, CD16 and
CD57) are usually negative, whereas the new specific
NK-cell markers CD94, PEN-5 (CD161) and NKp46 are
usually positive, but only if tested on frozen sections.50
CD7 and CD30 may be sporadically expressed. Cytotox-
ic granule-associated proteins (TIA-1, perforin and
granzyme B) are positive in most cases. Usually, the TCR
and immunoglobulin genes are in germline configura-
tion.51 In the vast majority of cases, EBV can be detect-
ed by means of various techniques (ICH, ISH and molec-
ular investigations) thus suggesting a possible patho-
genetic role for this virus.52 Various cytogenetic abnor-
malities, particularly del(6)(q21q25) and i(6)(p10) have
been reported, but so far no specific chromosomal
translocation has been identified.53
Differential diagnoses
Differential diagnoses are other T/NK malignancies
(i.e. blastic NK lymphoma/leukemia and SPLTCL), a few
cases of CD30 negative peripheral T-cell lymphoma and,
rarely, inflammatory processes. The presence of the EBV
(which is always negative in blastic NK lymphoma/leu-
kemia) is a useful and distinctive diagnostic parameter
coupled with the usual absence of the CD4. The pres-
ence of EBV, the antigenic profile, the germline config-
uration of the TCR and the clinical features also facili-
tate the distinction between the rare cases of this lym-
phoma characterized by pronounced subcutaneous
infiltrates and otherwise typical cases of SPLTCL.
Outcome and therapy
The prognosis of these lymphomas is variable but they
generally have an aggressive clinical behavior associat-
ed with a high mortality rate despite aggressive chemo-
therapy.45,47 To date, no real predictive prognostic mark-
er has been identified.
Blastic NK-cell lymphoma/leukemia
Clinical features and morphology
This unfrequent subtype of lymphoma/leukemia54 usu-
ally affects middle-aged or elderly patients. The lym-
phoma tends to involve multiple sites55 with a predilec-
tion for the skin and soft tissues; however, lymph nodes,
peripheral blood and bone marrow can also be involved.
Clinically the skin localizations appear as reddish to
bluish, often purpuric, nodules, tumors and/or infiltrat-
ed plaques (Figure 8A), sometimes ulcerated.56,57 Histo-
logically the skin lesions consist of a densely packed
dermal and often subcutaneous cellular infiltrate that
often shows a periadnexal and perivascular distribu-
tion. Cytologically, the neoplastic cells vary in size and
shape, from medium to pleomorphic to large elements
resembling myeloid blasts; chromatin is finely particu-
late and nucleoli are inconspicuous (Figure 8B). Apop-
totic phenomena and an angiocentric/angiodestructive
pattern are not prominent in blastic NK lymphoma.
Mitoses are frequent.
Immunohistochemistry, molecular biology
and cytogenetics
The neoplastic cells have a CD4+; CD56+ (Figure 8C);
CD43+; CD45RA+/−; CD123+; TDT+/−; TCL-1+/− phenotype;
CD68 is frequently expressed, whereas CD2, CD7, cyto-
plasmic CD3 and cytotoxic molecules (TIA-1, granzyme-
B) are variably expressed;56,57 some cases may be posi-
tive for CD34.58 There is no rearrangement of the TCR
and the search for EBV is always negative.58
Differential diagnoses
Because of the morphologic and, in part, antigenic
overlap between lymphoblastic and myeloblastic neo-
plasms the diagnosis of blastic NK lymphoma requires
caution and should only be made in the absence of
commitment to the T-cell or myeloid lineages (negativ-
ity for CD3s, MPO and CD33). These malignancies have
been variably classified and the cell of origin has been
proposed to be an NK-cell precursor, an immature mye-
lo-monocyte precursor, or a mixed NK/myelomonocyte
precursor. In the WHO lymphoma classification these
cases are considered as blastic NK-cell lymphoma.1
However, there are accumulating findings that reveal
very close similarities between the phenotypic features
of this lymphoma/leukemia and plasmacytoid dendrit-
ic cells (P-DC), thus suggesting their possible relation-
ship and origin from this subpopulation. Such a hypoth-
esis has been supported by in vitro experiments show-
ing that the leukemia cells may be modulated to func-
tion as P-DC and to secrete interferon-α. On such bases
it has been proposed to rename this entity as early pDC
leukemia/lymphoma.56 However, additional experimen-
tal investigations are required to clarify unequivocally
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the exact lineage from which the cells of the blastic-NK
lymphoma/leukemia originate.
Outcome and therapy
This lymphoma/leukemia usually pursues a very
aggressive clinical course and the disease often termi-
nates with massive bone marrow infiltration, overt
leukemia and sometimes neurological involvement.55 In
certain series the median survival after diagnosis was 30
months (ranging between 14 and 46 months).56 The
response to conventional regimens used for non-
Hodgkin’s lymphomas is poor but a partial one may be
achieved, at least in some cases, using an acute
leukemia-like regimen; however relapses rapidly occur.56
In a study only 2 allotransplanted patients were report-
ed as long survivors.57 It has been suggested that
patients with lesions confined to the skin may have a
better prognosis, but these observations need to be con-
firmed on larger series.59
Peripheral T-cell lymphoma, not
otherwise specified (PTL NOS) (WHO 2001)
Clinical features and morphology
This is a controversial category of T-cell malignan-
cies. The EORTC cutaneous lymphoma classification2 dis-
tinguished various subtypes of peripheral primary cuta-
neous T-cell lymphomas other than MF, namely, pri-
mary cutaneous CD30 negative large T-cell lymphomas
and the pleomorphic small/medium sized CTCL (includ-
ed among the provisional entities). In contrast, since a
number of distinct entities corresponding to recogniz-
able subtypes of nodal and/or extranodal T-cell malig-
nancies have already been separately described, the
WHO lymphoma classification1 found no clinical justi-
fication to subtype the remaining group of nodal and
(sporadically) extranodal T-cell malignancies further.
Thus, this group of T-cell lymphomas has been referred
to by using the term unspecified, highlighting that they
do not belong to any of the better defined entities.
However, irrespectively of the terminology adopted in
the different classifications, this heterogeneous cate-
gory of T-cell malignancies accounts for about 50% of
all peripheral T-cell lymphomas in western countries.
They usually affect adults and the elderly although there
are sporadic cases in children. The skin is often the site
of presentation of an otherwise systemic disease60 but
exceedingly rare examples of true primary cutaneous
forms exist and in two recent reports1-2, 61 the frequency
of these forms was 2.9% and 5% of all primary cuta-
neous lymphomas. Furthermore it seems that a small
minority of primary cutaneous T-cell lymphomas previ-
ously classified in this category can be separated as a
provisional entity: these include cutaneous γ/δ T-cell
lymphomas, aggressive epidermotropic CD8+ cytotoxic
lymphomas and small-medium pleomorphic CD4+ T-cell
lymphomas. Cases previously clinically diagnosed as MF
Figure 9A. Aggressive epidermotropic CD8+ cytotoxic
lymphoma: the patient presents a typical nodular lesion
with a central necrotic area on the right temporal area.
B. Histologically there is a lichenoid, strongly epider-
motropic pleomorphic lymphoid infiltrate (HE×100).
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tumeur d’emblée and some primary CTCL with angio-
centric features are probably included within this cat-
egory and are described below in more detail.
PTL NOS, rare variant: aggressive
epidermotropic CD8+ cytotoxic
lymphoma (AeCD8+cx)
Clinical features and morphology
AeCD8+cx lymphoma is a very rare form of cutaneous
T-cell lymphoma, first reported by Jensen et al. in 1980.62
In 1999 Berti et al.63 reported 8 cases of AeCD8+cx lym-
phoma and compared them with 9 cases expressing
CD8+, but classifiable as indolent lymphomas (MF or
CD30+-like disorders), suggesting a possible new entity
with an aggressive clinical behavior. The clinical pres-
entation is characterized by a sudden eruption of local-
ized or disseminated nodules with central necrosis, (Fig-
ure 9A) or by superficial, hyperkeratotic patches and
plaques as in pagetoid reticulosis (Ketron-Goodman
type). AeCD8+cx lymphomas histologically show an
acanthotic or atrophic epidermis, necrotic keratinocytes
and moderate to marked spongiosis, with blister for-
mation. Tumor cells are small to medium or medium to
large with pleomorphic or blastic nuclei (Figure 9B).
Prominent epidermotropism was observed in late
tumor lesions, with a linear configuration in the basal
cell layer or involvement of the entire epidermis with a
pagetoid pattern; adnexal involvement, angiocentricity
and angioinvasion were frequently observed.36,64
Immunohistochemistry, molecular biology
and cytogenetics
AeCD8+cx lymphomas express a β-F-1+, CD3+, CD8+,
TIA−1+, CD45RA+, CD45RO−, CD2−, CD5−, phenotype.36, 64
No consistent genetic alterations have been identified,
and there is no involvement of EBV or other oncogenic
viruses.
Differential diagnoses
SPTCL, nasal and extranasal NK/T T-cell lymphoma,
γ/δ T-cell lymphoma, rare cases of mycosis fungoides,
and CD30+ primary cutaneous anaplastic lymphomas
may express CD8+ in the context of different clinico-
pathologic and immunohistochemical features.63,65
Outcome and therapy
Patients frequently show simultaneous visceral
involvement or progression to visceral sites in less than
6 months. Polychemotherapy with or without doxoru-
bicin and radiotherapy are the most frequently used
forms of therapy. The median survival of the 8 analyzed
patients with AeCD8+cx lymphoma was 32 months.63
PTL/U, rare variant: primary cutaneous
γ/δT-cell lymphoma (PCGD-TCL)
Clinical features and morphology
PCGD-TCL is characterized by disseminated plaques
and/or necrotic nodules and tumors.66-69 (Figure 10A),
which occur more frequently on the extremities.69-70 The
Figure 10 A. Cutaneous γ/δ T-cell lymphoma. The ulcer-
ated, necrotic nodule is localized on the arm. B. TCR-δ 1
immunostaining (frozen section) is strongly positive on
lymphoma cells (APAAP, 200×).
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lymph nodes, spleen and bone marrow are not usually
involved but the disease may disseminate to extran-
odal/ mucosal sites. Histologically the infiltrate is
formed by medium to large pleomorphic cells, with
coarsely clumped chromatin and a few large blastic cells
with vesicular nuclei and prominent nucleoli. Angioin-
vasion, apoptosis and necrosis are common.  Three
major histologic patterns of involvement can be
observed: epidermotropic, dermal, and subcutaneous.
Epidermal infiltration is variable, from mild epider-
motropism to marked pagetoid pattern.63,71-73 Subcuta-
neous involvement may be panniculitis-like or more
dense, without lymphocytes rimming the fat cells or
foamy histiocytes. There is frequently co-existing der-
mal, epidermal and subcutaneous involvement. 
Immunophenotype, molecular biology and
cytogenetics
Neoplastic cells are TCR-δ-1+ (Figure 10B), CD3+,
CD2+, CD7+/−, CD5−.67 Most cases lack CD4 and CD8 mark-
ers although some are CD8+.66 The cells are positive for
TIA-1 and the cytotoxic proteins granzyme B, and per-
forin.74 CD56 is frequently expressed. The cells usually
show clonal rearrangement of the TCRγ and TCRδ genes.
TCRβ may be rearranged or deleted, but is not
expressed. EBV is generally negative in PCGD-TCL.75
Differential diagnosis
The features of PCGD-TCL overlap with those of some
cases of subcutaneous panniculitis-like T-cell lym-
phoma (SPTCL) and PCGD-TCL shares many features
with other extranodal (usually CD8+) cytotoxic T-cell
lymphomas.69 A similar and closely related disease may
present in mucosal sites; the exact relationship between
γ/δ TCL in cutaneous and other extranodal sites is
unclear.75
Outcome and therapy
PCGD-TCL is an aggressive disease resistant to mul-
tiagent chemotherapy regimens and/or radiation.63,73
Infact, 66% (22 of 33) of analyzed patients were dead
within 5 years of diagnosis; TCR-δ-1 expression was a
negative prognostic index (p <0.0001).73
PTL/U: pleomorphic small/medium
CD4+ lymphoma
Clinical features and morphology
This lymphoma is considered as a provisional entity in
the EORTC classification2 and does not fall into a spe-
cific category in the WHO classification, thus being
termed as PTL/UN.1 The patients must present with pri-
mary cutaneous papules and nodules without any sign
of precursor lesions of MF, even during the follow-up.
Two types of presentation and clinical course can be
seen: some patients show solitary nodules, commonly
located on the face, neck and upper part of the trunk,
while others develop groups of papules, nodules and
plaques in different sites of the body.76,77 Patients are
usually adults with a median age of 65 years,78 but iso-
lated lesions can also be observed in children. The prog-
nosis is favorable in the case of localized lesions61 and
the lesions can be treated surgically or irradiated, while
in cases with disseminated lesions the disease show an
intermediate grade of aggressivity,78 characterized by
frequent relapses and progression to lymph nodes and
visceral organs, in spite of radio-polychemotherapy. The
localized lesions show a nodular infiltrate in the entire
dermis formed by pleomorphic small to medium-sized
lymphocytes, with focal epidermotropism and a perivas-
cular and periadnexal distribution, with possible gran-
ulomatous reactions.
Immunohistochemistry, molecular biology
and cytogenetics
In the case of localized lesions the infiltrate express-
es the CD3+, CD4+, CD7+/−, CD45RO+ phenotype. In case
of multiple tumoral lesions some pan T-cell markers
(CD2, CD5) can be lost and the cells may express CD30
or CD56. A variable number of reactive B-lymphocytes
and many macrophages can be present. 
The infiltrate is usually clonal; no specific cytogenet-
ic alterations have been reported.
Differential diagnosis
The existence of this entity is debated, mainly because
of its clinicopathologic similarities with mycosis fun-
goides (unilesional MF, tumeur d’emblée MF) and in
some cases also with pseudolymphomas of the T-cell
type.
Outcome and therapy
Localized cutaneous pleomorphic small/medium T-
cell lymphoma is usually confined to the skin and can
be treated surgically or by local radiotherapy. In the
case of multiple lesions and progression, locoregional
lymph nodes are involved and the patients should be
treated by conventional polychemotherapy. 
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